India’s NPPA to Reconsider Retail Price Fixing for Cipla’s Combo Inhaler

India’s National Pharmaceutical Pricing Authority (NPPA) has been told by the Department of Pharmaceuticals (DoP) to consider Cipla’s retail pricing application for a combination inhaler drug. The decision comes after years of legal struggles surrounding similarities between the drug, a combination of Formoterol Fumarate Dihydrate 6mcg and Beclomethasone Dipropionate IP 100 mg, and one of its competitors.

According to Farhat Nasim, “In a meeting on July 31, 2019, MDC noted that the composition of the prpoduct was the same as that of Lupin Ltd, as included in the working sheet and the documents submitted by Cipla did not substantiate the study reports related to its product.“

To read more, click here.

(Source: Medical Dialogues, November 5^th, 2022)